230 CD/UC/nonIBD microbial patterns (HMP2 validation) ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● 10 20 30 40 50 CD nonIBD UC Freq P <2.2e-16 P <2.2e-16 P =0.08 ● ●● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● −10 0 10 −20 −10 0 10 20 PCA1 PCA2 Location ● ● Colon Ileum ● ●● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ●● ●● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● −15 −10 −5 0 5 10 15 −20 0 20 PCA1 PCA2 is_inflamed ● ● No Yes ● ● 0 1 2 3 4 CD nonIBD UC shannon ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● −10 0 10 −20 −10 0 10 20 PCA1 PCA2 UC is more similar to nonIBD than CD IBD has larger microbial variation than nonIBD P =0.04 P =0.2 P =2.02e-3 Aitchison's distance Dissimilarities A C B Extended Data Figure S4 Extended Data Figure S4 | Replication of overall mucosal microbiota characterization in patients with IBD and non-IBD controls. Replication was performed in data derived from the HMP2 cohort study.13 a, Microbial alpha-diversity (Shannon index) was lowest in patients with CD (n=85) compared to patients with UC (n=46) and non-IBD controls (n=45). b, PCA plots based on Aitchison’s distances and stratified by tissue location and inflammatory status (colors as in a). c, PCA plot showing microbial dissimilarity (Aitchison’s distances) in CD, UC and non-IBD controls, Microbial dissimilarity is highest in samples from patients with CD, followed by patients with UC and non-IBD controls. CD, Crohn’s disease; PCA, principal component analysis; UC, ulcerative colitis.
RkJQdWJsaXNoZXIy MjY0ODMw